03:01 on October 9, 2021, Beijing time, OTC market in the United StatesWUHAN GENERAL GP (WUHN.us)There was a change in the stock, and the share price fell rapidly by 6.83%. As of press time, the stock was trading at US $0.401 per share, with a turnover of 5002 shares, a turnover rate of 0.01% and an amplitude of 4.53%.
Recent earnings data show that the stock achieved operating income of $2362.00, net profit of-$281603.00, earnings per share of-$0.01and gross profit of $419.00, with a price-to-earnings ratio of-50.12 times.
In terms of agency rating, there is currently no agency to make "buy, hold, sell" recommendations on the stock.
The pharmaceutical industry in which WUHAN GENERAL GP shares are listed on the US OTC market rose 0.1 per cent as a whole. Among its related stocksEndo Pharmaceutical、Aerie Pharmaceuticals Inc、Ani Pharmaceuticals IncThe increase is relatively large.Agile Therapeutics Inc、Sundial Growers Inc、Flora Growth Corp.The turnover rate was 15.12%, 9.79% and 8.89% respectively, and the related stocks with larger amplitude were Flora Growth Corp., and the turnover rates were 15.12%, 9.79% and 8.89%, respectively.Jupiter Wellness Inc C/Wts 170.06 Universe 2025 (To Pur Com)And Endo Pharmaceuticals, the amplitudes were 17.20%, 14.64% and 14.01%, respectively.
About WUHAN GENERAL GP in American OTC Market: M2Bio Sciences Inc, formerly known as WUHAN GENERAL GP Group (China) Co., Ltd., is an alternative pharmaceutical company dedicated to the application of emerging technologies and clinical research and health applications of cannabinol (CBD)-based drugs in the human and pet care industries in Canada, the United States, Europe and Australia for cancer, cardiovascular disease, and mental illness. Chronic pain and other diseases. It provides medical-grade CBD products and quality patient care.
(the above content is completed by Money Call, a self-selected intelligent machine writer, and is only used as a reference for users to look at the market, not as a basis for transaction. )